Home
About Us
About Us
About Us
Team
Investors
Partners
Careers
Find out more about who we are, what we do and the people behind Epitopea.
Our Platform
Our Platform
CryptoMap
TM
Publications
Find out what makes us unique and the work we do with our revolutionary CryptoMap
TM
platform.
Pipeline
Pipeline
CryptiVax
TM
Therapeutics Focus
News & Events
News & Events
All News & Events
Press Releases
In the news
Events
All the latest company news, press releases and updates from Epitopea.
Language
Language
Français
English
Contact
News & Events:
Press Releases
Revealing the true targets for next generation immunotherapies.
Learn More
Epitopea Awarded Grant from Innovate UK’s Cancer Therapeutics Programme
Date:
September 12, 2024
|
Press Releases
Grant to advance development of Cryptigen immunotherapeutics for cancer CAMBRIDGE, UK and MONTREAL, CANADA, 12 September 2024 - Epitopea, a […]
Read More
Epitopea Announces Leadership Transition and New Appointments
Date:
July 25, 2024
|
Press Releases
Alan C. Rigby Joins as CEO, Jon Moore Transitions to CSO CAMBRIDGE, UK and MONTREAL, CANADA, 25 July 2024 - […]
Read More
Epitopea Announces $14 Million Financing to Advance Cancer Immunotherapeutics
Date:
April 25, 2022
|
Press Releases
Novel CryptigenTM technology unlocks full potential of Tumour Specific Antigens CAMBRIDGE, UK and MONTREAL, CANADA, 25 April 2022 - Epitopea, […]
Read More
« Previous
1
2
Categories
In The News
Press Releases
Recent News & Events
Epitopea Announces Approval of OVACT Clinical Trial Application for CryptiVax-1001 in Advanced High-Grade Serous Ovarian Cancer
Epitopea Strengthens Scientific Advisory Board with Appointment of Leading Authority in Cancer, Lisa Butterfield
Epitopea Featured in GEN
Revealing Novel Targets For Next Generation Immunotherapies
Quick Links
Home
About Us
Platform
News & Events
Contact
Information
Careers
Disclaimer
Privacy & Cookie Policy
Terms & Conditions
Follow us on social media
© 2022 – 2026 Epitopea Ltd | All Rights Reserved
Created by
FDM Digital
linkedin-square
angle-down